[ad_1]
15 consecutive quarters of revenue growth for S&P 500 companies — not enough to support current prices.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...